Seeking Alpha
View as an RSS Feed


View DoctoRx's Articles BY TICKER:
  • The Case For A Biotech-Bonds Barbell Strategy: Focus On Several Junior Biotech Stocks
    Editors' Pick  • Yesterday, 12:50 PM AAPL, ALNY, ALXN 13 Comments
  • More Carnage In Junior Biotechs: General Comments With Focus On Opko And Acceleron
    Editors' Pick  • Wed, Sep. 30 OPK, XLRN 92 Comments
  • Biotechs Battered: Comments On All 6 Major Biotech Stocks
    Editors' Pick  • Mon, Sep. 28 ABBV, ABT, AMGN 287 Comments
  • Reassessing Biotech Stocks After The Renewed Sell-Off: Focus On Regeneron
    Tue, Sep. 22 REGN 136 Comments
  • Gilead Provides An Update: Review And Analysis Of Wednesday's Q&A
    Editors' Pick  • Thu, Sep. 17 GILD 120 Comments
  • Mr. Market Errs: Apple Is Unlikely To Be Stopped In Its Rise To Further Heights
    Thu, Sep. 10 AAPL 200 Comments
  • Amgen Vs. Regeneron In The PCSK9i War, With Comments On Competitive Threats
    Thu, Sep. 10 AMGN 54 Comments
  • A Review Of NantKwest, Dr. Soon-Shiong's Immuno-Oncology Company
    Tue, Sep. 8 NK 34 Comments
  • Review Of Biotechs (Part 3 Of 3): Focus On Small-Caps; Initiating Coverage Of OPKO
    Editors' Pick  • Wed, Sep. 2 OPK 85 Comments
  • Biotech Review (Part 2 Of 3): New Coverage Of Some Mid-Caps With Update On Intercept
    Mon, Aug. 31 ICPT 37 Comments
  • Comments On The Market Correction; Focus On Biotechs: Large Caps
    Editors' Pick  • Wed, Aug. 26 REGN 114 Comments
  • Gilead's Pipeline, Part 3, With Summary Comments
    Editors' Pick  • Mon, Aug. 24 GILD 126 Comments
  • A Review Of Gilead's Pipeline (Part 2): Focus On Zydelig And Lymphoma/CLL Candidates
    Thu, Aug. 20 GILD 76 Comments
  • A Review Of Gilead's Pipeline (Part 1)
    Tue, Aug. 18 GILD 112 Comments
  • Apple Drops, Becomes More Attractive As It Aims For Total Victory Over Android And Windows
    Fri, Aug. 14 AAPL 314 Comments
  • Isis Pharma Stock Drops On Good News: Re-Evaluating The Bull Case
    Thu, Aug. 13 ISIS 64 Comments
  • An Analysis Of Achillion, A Play On Johnson & Johnson's New Efforts In The Hepatitis C Market
       • Thu, Aug. 13 ACHN 40 Comments
  • Shaken, Not Stirred: Is The 'Biotech Bubble' Beginning To Burst?
    Editors' Pick  • Fri, Aug. 7 ICPT 187 Comments
  • Regeneron Aims For $1000 As Its Growth Accelerates Yet Again
    Tue, Aug. 4 REGN 44 Comments
  • A Post-Earnings Review Of Amgen, With Discussion Of The Repatha Launch
    Mon, Aug. 3 AMGN 53 Comments
  • Gilead Beats And Raises: Thinking Through The Future Of Its Business And Its Stock Price
    Wed, Jul. 29 GILD 277 Comments
  • The Importance Of Newly-Released Data For Gilead's HIV Drug Patent Cliff
    Mon, Jul. 27 GILD 77 Comments
  • Biogen Falls Hard: Is It Undervalued Now?
    Mon, Jul. 27 BIIB 55 Comments
  • An Assessment Of Celgene's Deal For Receptos
    Tue, Jul. 21 CELG 43 Comments
  • An Analysis Of Intercept Pharma, An Innovator In Serious Liver Diseases With Unmet Needs
    Editors' Pick  • Wed, Jul. 15 ICPT 63 Comments
  • A Pre-Earnings Look At Gilead Sciences
    Tue, Jul. 14 GILD 247 Comments
  • Apple: Lots Of Smoke (FUD), But What's On Fire Are Earnings And Growth Opportunities
    Fri, Jul. 10 AAPL 207 Comments
  • Biotech At A Fraught Mid-Year: An Overview And Look Ahead
    Thu, Jul. 9 ABBV, ACHN, ADXS 98 Comments
  • Multiple Observations On Celgene's Latest Licensing Deals, And Its Valuation
       • Fri, Jul. 3 CELG 75 Comments
  • Vertex Pharma: Well Positioned To Set New Highs
    Fri, Jun. 26 VRTX 24 Comments
  • Is Biotech Finally In A Bubble?
    Editors' Pick  • Fri, Jun. 19 ABBV, ACHN, ALXN 246 Comments
  • Amgen, Regeneron LDL-Lowering Drugs Provide Major Upside Potential To Their Stocks
    Mon, Jun. 15 AMGN 52 Comments